Immunity & Liver Cancer: New Treatment Eradicates Tumors in Mice
- A protein known for stimulating red blood cell production, erythropoietin, or EPO, also plays a critical role in suppressing the immune system's response to cancer, researchers have found.
- Research in mice showed that blocking EPO activity converted immune-resistant liver tumors into ones vulnerable to immune attack.
Scientists have discovered EPO’s unexpected role in suppressing cancer immunity, a major breakthrough in understanding how tumors evade the immune system. Blocking EPO activity transformed immune-resistant liver tumors in mice, paving the way for potentially groundbreaking therapies. Combining EPO blockade with immunotherapy led to complete tumor regression adn extended survival,offering hope for novel cancer treatments. Elevated EPO levels correlate with poorer outcomes in various cancers, highlighting the importance of this revelation. This research could revolutionize immunotherapy for liver cancer and beyond. Read the full story at News Directory 3 to uncover how these findings may lead to new avenues for treating liver cancer and other malignancies. Discover what’s next …
Surprising Role of EPO Protein in Blocking Cancer Immunity Discovered
Updated June 20, 2025
A protein known for stimulating red blood cell production, erythropoietin, or EPO, also plays a critical role in suppressing the immune system’s response to cancer, researchers have found. This finding about the EPO protein’s role could lead to new cancer therapies.
Research in mice showed that blocking EPO activity converted immune-resistant liver tumors into ones vulnerable to immune attack. Combining this blockade with immunotherapy resulted in complete tumor regression in most cases, with treated animals surviving the duration of the experiment. Control animals, conversely, survived only weeks.
Dr. Edgar Engleman, professor of pathology and medicine, called the finding a “fundamental breakthrough” in understanding